Big banks kick off earnings season Friday, and many analysts expect robust results after a post-election stock-trading frenzy that may have provided stronger revenue.
Lined up for tomorrow are Bank of America Corp(NYSE: BAC), JPMorgan Chase & Co. (NYSE: JPM), and Wells Fargo & Co (NYSE: WFC), and there’s plenty of enthusiasm going into the results. The financial sector overall....more>>>
The shares of United Parcel Service (NYSE:UPS) remain too expensive for us to buy despite our desire to add one more dividend growth stock to our taxable account portfolio. Unfortunately, we missed out on our chance to buy the company’s shares earlier in 2016 when an overall market sell off presented us with the opportunity to purchase the shares under $100. UPS shares not only broke down....more>>>
Ever the diplomat, Mark Zuckerberg has cleared the air regarding one of his board member’s comments on India.
On Tuesday, venture capitalist Marc Andreessen — who’s a Facebook (FB, Tech30) board member — posted a series of controversial tweets on Twitter. In them, he expressed his dissatisfaction with the ruling by an India regulator that effectively killed Faceook’s....more>>>
JMP analyst Devin Ryan argues that Goldman Sachs (GS) “is at the forefront of a tech revolution on Wall Street.” He explains:
We recently met with senior management at Goldman Sachs, including Marty Chavez, who runs the Technology business, and Paul Russo, who co-heads Equities Sales & Trading. We walked away with a greater appreciation for the firm’s....more>>>
Related ULTA Mid-Day Market Update: FEI Company Rises Following Acquisition News; Terex Shares Drop Cramer Is Watching Ulta Salon And Time Warner Today Dycom, Ulta, Veeva Deliver Strong Results; Broadcom Up Next (Investor’s Business Daily) Related SCOR Mid-Day Market Update: FEI Company Rises Following Acquisition....more>>>
Today, Gilead Sciences (GILD) announced that European regulators had approved its new hepatitis-C treatment. Maxim’s Jason Kolbert and Jason McCarthy contend that this is just another reason Gilead will remain dominant in hepatitis-C:
Gilead announced that the European Commission (EC) approved its new pan-genotypic HCV product Epclusa (sofosbuvir 400 mg/velpatasvir....more>>>
AQR Capital Management’s Cliff Asness has launched a healthy discussion about the trials and tribulations of factor timing with a new essay (“The Siren Song of Factor Timing”). He’s recommends that investors steer clear, which is good advice because the crowd’s record, in the aggregate, to successfully engage in market-timing activities generally is overwhelmingly poor.....more>>>
Related AXP The Market In 5 Minutes: Friday, March 11, 2016 The Market In 5 Minutes: Tuesday, March 8, 2016 Jeff Ubben Exits Position in American Express (GuruFocus) Related DFS First Solar, GameStop, Chipotle Lead List Of March's Best Performers Over Past Decade Avoid Credit Card Stocks?....more>>>
Traders are racing to rethink their views on the paceof Federal Reserve interest-rate increases after a stronger than expected reading on inflation. The question now is whetherthe datawill remain strong enough to keep the market buoyant.
So-called core inflation, which strips out volatile food and energy categories, rose 0.3% last month,....more>>>